MedTrace Logo

Predicting Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma

NCT06476067 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2025-07-11

No results posted yet for this study

Summary

The prognosis of patients with esophageal squamous cell carcinoma (ESCC) who develop post-operative early tumor recurrence is often relatively poor. Therefore, biomarker that can detect micro metastases before the start of treatment is required. Epigenomic alterations such as DNA methylation have attracted attention as promising biomarkers. The investigators aim to predict early recurrence based on whole genome DNA methylation analysis of esophageal cancer.

Conditions

  • Esophageal Cancer
  • Recurrence
  • DNA Methylation

Interventions

PROCEDURE

Surgery

Esophagectomy

Sponsors & Collaborators

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Koichi Takiguchi, PhD · City of Hope Medical Center

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-01
Primary Completion
2026-06-18
Completion
2026-06-18

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06476067 on ClinicalTrials.gov